Abstract OT3-02-06: A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Autor: Kari B. Wisinski, RS DiPaola, Ticiana Leal, Jens C. Eickhoff, Jill M. Kolesar, Glenn Liu, JA Mullvain

Publikováno v: Cancer Research. 76:OT3-02

Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and are activated by DNA strand breaks. DNA damage from carboplatin has been associated with activation of PARP. Preclinical data indicate that PARP inhibition potentia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04e437576035369564feaf24d20b95b1
https://doi.org/10.1158/1538-7445.sabcs15-ot3-02-06

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.

Autor: Appleman LJ; UPMC Hillman Cancer Center, Pittsburgh, PA., Kim SE; Dana-Farber Cancer Institute, Boston, MA., Harris WB; Emory University and Atlanta VA Medical Center, Atlanta, GA., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, CA., Pins MR; Rosalind Franklin University, Chicago, IL., Kolesar J; University of Kentucky, Lexington, KY., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Parikh RA; University of Kansas, Kansas City, KS., Vaena DA; West Cancer Center, Germantown, TN., Ryan CW; University of Oregon Health & Science University, Portland, OR., Hashmi M; Stormont-Vail HealthCare, Topeka, KS., Costello BA; Mayo Clinic, Rochester, MN., Cella D; Northwestern University Feinberg School of Medicine, Chicago, IL., Dutcher JP; Our Lady of Mercy, Bronx, NY., DiPaola RS; University of Kentucky, Lexington, KY., Haas NB; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA., Wagner LI; Wake Forest University, Winston-Salem, NC., Carducci MA; Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 10; Vol. 42 (17), pp. 2061-2070. Date of Electronic Publication: 2024 Mar 26.

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.

Autor: Carthon BC; Department of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA., Kim SE; Department of Statistics, Dana-Farber Cancer Institute, Boston, MA., McDermott DF; Division of Hematology/Oncology; Beth Israel Deaconess Medical Center, Boston, MA., Dutcher JP; Cancer Research Foundation of New York, Chappaqua, NY., Puligandla M; Department of Statistics, Dana-Farber Cancer Institute, Boston, MA., Manola J; Department of Statistics, Dana-Farber Cancer Institute, Boston, MA., Pins M; Department of Pathology; Advocate Lutheran General Hospital, Park Ridge, IL., Carducci MA; Division of Hematology /Oncology; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD., Plimack ER; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA., Appleman LJ; Department of Medicine; University of Pittsburgh Medical Center, Pittsburgh, PA., MacVicar GR; Department of Medicine; Illinois Cancer Care, Peoria, IL., Kohli M; Department of Medicine; University of Utah, Salt Lake City, UT; Department of Medicine; Mayo Clinic, Rochester, MN., Kuzel TM; Department of Medicine; Northwestern University, Chicago, IL., DiPaola RS; Department of Medicine; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Haas NB; Department of Medicine; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA. Electronic address: naomi.haas@pennmedicine.upenn.edu.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Oct; Vol. 21 (5), pp. 546-554. Date of Electronic Publication: 2023 Jul 03.

A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer.

Autor: Myint ZW; Department of Medicine, Division of Medical Oncology, University of Kentucky, Lexington, KY 40536, USA.; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA., St Clair WH; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Radiation Medicine, University of Kentucky, Lexington, KY 40536, USA., Strup SE; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Urology, University of Kentucky, Lexington, KY 40536, USA., Yan D; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY 40536, USA., Li N; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY 40536, USA., Allison DB; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA., McLouth LE; Department of Behavioral Science, University of Kentucky, Lexington, KY 40536, USA., Ellis CS; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA., Wang P; Department of Medicine, Division of Medical Oncology, University of Kentucky, Lexington, KY 40536, USA.; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA., James AC; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Urology, University of Kentucky, Lexington, KY 40536, USA., Hensley PJ; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; Department of Urology, University of Kentucky, Lexington, KY 40536, USA., Otto DE; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA., Arnold SM; Department of Medicine, Division of Medical Oncology, University of Kentucky, Lexington, KY 40536, USA.; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA., DiPaola RS; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA., Kolesar JM; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.; College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA.

Publikováno v: Cancers [Cancers (Basel)] 2023 Apr 27; Vol. 15 (9). Date of Electronic Publication: 2023 Apr 27.

Optimizing team science in an academic medical center: A qualitative examination of investigator perspectives.

Autor: Surratt HL; Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, USA.; Center for Clinical and Translational Science, University of Kentucky, Lexington, KY, USA., Otachi JK; University of Kentucky Health Care, Psychiatric Services, Lexington, KY, USA., Slade E; Department of Biostatistics, University of Kentucky, College of Public Health, Lexington, KY, USA., Kern PA; Center for Clinical and Translational Science, University of Kentucky, Lexington, KY, USA.; Department of Internal Medicine, Division of Endocrinology, University of Kentucky College of Medicine, Lexington, KY, USA., King V; Center for Clinical and Translational Science, University of Kentucky, Lexington, KY, USA.; Department of Internal Medicine, Division of Cardiology, University of Kentucky College of Medicine, Lexington, KY, USA., Kelly TH; Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, USA.; Center for Clinical and Translational Science, University of Kentucky, Lexington, KY, USA., DiPaola RS; Office of the Provost, University of Kentucky, Lexington, KY, USA.

Publikováno v: Journal of clinical and translational science [J Clin Transl Sci] 2023 Jan 23; Vol. 7 (1), pp. e57. Date of Electronic Publication: 2023 Jan 23 (Print Publication: 2023).